Kapitalo Investimentos Ltda Makes New $36,000 Investment in CVS Health Co. (NYSE:CVS)

Kapitalo Investimentos Ltda bought a new position in CVS Health Co. (NYSE:CVS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 456 shares of the pharmacy operator’s stock, valued at approximately $36,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in CVS Health by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 117,696,285 shares of the pharmacy operator’s stock worth $9,293,299,000 after purchasing an additional 533,659 shares in the last quarter. Capital World Investors lifted its position in shares of CVS Health by 0.3% in the fourth quarter. Capital World Investors now owns 40,544,702 shares of the pharmacy operator’s stock worth $3,201,410,000 after buying an additional 119,631 shares in the last quarter. Capital International Investors boosted its stake in CVS Health by 47.4% during the fourth quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock valued at $2,660,298,000 after buying an additional 10,837,801 shares during the last quarter. Northern Trust Corp grew its holdings in CVS Health by 2.2% during the 3rd quarter. Northern Trust Corp now owns 14,214,296 shares of the pharmacy operator’s stock valued at $992,442,000 after buying an additional 305,564 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of CVS Health by 2.2% during the 3rd quarter. Royal Bank of Canada now owns 14,136,920 shares of the pharmacy operator’s stock worth $987,041,000 after acquiring an additional 303,512 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig purchased 1,000 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were acquired at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the acquisition, the director now owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is currently owned by insiders.

CVS Health Price Performance

CVS opened at $61.01 on Friday. The company has a market capitalization of $76.59 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 0.58 and a beta of 0.53. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. CVS Health Co. has a 12-month low of $52.77 and a 12-month high of $83.25. The business’s fifty day simple moving average is $60.62 and its 200-day simple moving average is $70.71.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same quarter in the previous year, the company earned $2.20 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. On average, equities research analysts anticipate that CVS Health Co. will post 7.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CVS. Leerink Partnrs lowered shares of CVS Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 1st. Truist Financial restated a “buy” rating and issued a $66.00 target price (down from $90.00) on shares of CVS Health in a report on Thursday, May 2nd. Barclays dropped their price target on CVS Health from $78.00 to $63.00 and set an “equal weight” rating for the company in a research report on Thursday, May 2nd. JPMorgan Chase & Co. decreased their price objective on CVS Health from $101.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Finally, Robert W. Baird began coverage on CVS Health in a research report on Thursday, May 30th. They set a “neutral” rating and a $61.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $75.05.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.